^
BIOMARKER:
KRAS G12A
i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
›
KRAS G12A
|
CRC
|
KRAS G12A
|
CRC
|
cetuximab Resistant: B - Late Trials
|
cetuximab Resistant: B - Late Trials
|
KRAS G12A
|
CRC
|
KRAS G12A
|
CRC
|
panitumumab Resistant: B - Late Trials
|
panitumumab Resistant: B - Late Trials
|
KRAS G12A
|
CML
|
KRAS G12A
|
CML
|
GT19077 Sensitive: C3 – Early Trials
|
GT19077 Sensitive: C3 – Early Trials
|
KRAS G12A
|
Ovarian Serous Adenocarcinoma
|
KRAS G12A
|
Ovarian Serous Adenocarcinoma
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
VS-6766 + VS-6063 Sensitive: C3 – Early Trials
|
KRAS G12A
|
HCC
|
KRAS G12A
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
KRAS G12A
|
NSCLC
|
KRAS G12A
|
NSCLC
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
KRAS G12A
|
NSCLC
|
KRAS G12A
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
KRAS G12A
|
NSCLC
|
KRAS G12A
|
NSCLC
|
regorafenib Sensitive: C4 – Case Studies
|
regorafenib Sensitive: C4 – Case Studies
|
KRAS G12A
|
Lymphoma
|
KRAS G12A
|
Lymphoma
|
GT19077 Sensitive: D – Preclinical
|
GT19077 Sensitive: D – Preclinical
|
KRAS G12A
|
Multiple Myeloma
|
KRAS G12A
|
Multiple Myeloma
|
GT19077 Sensitive: D – Preclinical
|
GT19077 Sensitive: D – Preclinical
|
KRAS G12A
|
AML
|
KRAS G12A
|
AML
|
GT19077 Sensitive: D – Preclinical
|
GT19077 Sensitive: D – Preclinical
|
KRAS G12A
|
CLL
|
KRAS G12A
|
CLL
|
GT19077 Sensitive: D – Preclinical
|
GT19077 Sensitive: D – Preclinical
|
KRAS G12A
|
CRC
|
KRAS G12A
|
CRC
|
sunitinib Resistant: D – Preclinical
|
sunitinib Resistant: D – Preclinical
|
